|
T22323 |
Enoxaparin sodium
|
|
Thrombin
|
|
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percu... |
|
T2171 |
SEW2871
|
SEW2871 |
S1P Receptor
,
LPL Receptor
|
|
SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, an... |
|
T12883 |
Fezagepras
|
PBI-4050,Setogepram |
GPR
|
|
Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions. |
|
T8505 |
SC-236
|
Sc 236 |
Apoptosis
,
COX
,
PPAR
|
|
SC-236 (Sc 236) is an orally active and selective inhibitor of COX-2 (IC50 of 0.005 μM and 17.8 μM for COX-2 and COX-1, respectively). |
|
T9010 |
IMM-H007
|
|
Others
,
AMPK
|
|
IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression |
|
T60226 |
CT52923
|
|
PDGFR
|
|
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological dis... |
|
T76664 |
Adropin (34-76) (human, mouse, rat)
|
|
|
|
Adropin (34-76) (human, mouse, rat) is a peptide that attenuates liver fibrosis and insulin resistance independent of obesity or food intake. |
|
T15549 |
Icosabutate
|
NST-4016,PRC-4016 |
Others
|
|
Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hyper... |
|
T73446 |
BI‑3231
|
|
Dehydrogenase
|
|
BI‑3231 is a selective and potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 HSD17B13, inhibiting hHSD17B13 and mHSD17B13.BI-3231 can be used for the study of alcohol-associated liver injury, fibrosis and cirrhosis... |
|
TP2110L |
TAT-Gap19 acetate
|
|
Gap Junction Protein
|
|
TAT-Gap19 acetate is a specific inhibitor of connexin43 hemichannel (Cx43 HC). TAT-Gap19 acetate traverses the blood-brain barrier and alleviates liver fibrosis in mice. TAT-Gap19 acetate does not inhibit the correspondi... |
|
T67961 |
Safironil
|
|
Others
|
|
safironil is a novel antifibrotic compound and a competitive inhibitor of collagen synthesis. safironil inhibited in vitro experiments on fibroblast activation monitored by collagen I mRNA or smooth muscle alpha-actin le... |
|
T40296 |
MCA17-1
|
MCA17-1 |
|
|
MCA17-1 exhibits superior bioactivity compared to the positive control, obeticholic acid (OCA), in the treatment of liver fibrosis. |
|
T40943 |
EMD527040
|
|
|
|
EMD527040 is a powerful and highly specific αvβ6 antagonist, exhibiting notable antifibrotic properties. It is suitable for conducting research on carcinoma and liver fibrosis. |
|
T37842 |
ASB 14780
|
|
|
|
Potent and selective cytosolic phospholipase A2 alpha (cPLA2α) inhibitor (IC50 = 20 nM). Selective for cPLA2α over secreted PLA2α (sPLA2α; exhibits no inhibition at 10 μM). Inhibits cPLA2α-dependent inflammatory respons... |
|
T39074 |
(Rac)-Zevaquenabant
|
(Rac)-MRI-1867,(Rac)-Zevaquenabant |
|
|
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of the cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (Ki) of 5.7 nM sp... |
|
T78790 |
J-1048
|
|
|
|
J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/Smad signaling pathway [1]. |
|
T79207 |
SUCNR1-IN-1
|
|
|
|
SUCNR1-IN-1 (Compound 20) serves as a potent SUCNR1 inhibitor, exhibiting an IC50 of 88 nM against hSUCNR1. It is utilized in the study of rheumatoid arthritis, liver fibrosis, and obesity [1]. |
|
T74996 |
FXR agonist 3
|
|
|
|
FXR agonist 3, an anti-NASH (Non-Alcoholic Steatohepatitis) agent, functions by activating FXR. It demonstrates anti-fibrogenic activity by inhibiting the expression of COL1A1, TGF-β1, α-SMA, and TIMP1. Additionally, it ... |
|
T75821 |
TAT-Gap19 TFA
|
|
|
|
TAT-Gap19 TFA, a Cx mimetic peptide and specific connexin43 hemichannel (Cx43 HC) inhibitor, does not inhibit the corresponding Cx43 gap junction channels (GJCs). It crosses the blood-brain barrier and has been shown to ... |
|
T62301 |
J-1063
|
|
|
|
J-1063 is a selective, orally active and potent inhibitor of ALK5 (IC50: 0.039 μM). J-1063 inhibits inflammatory infiltration, collagen deposition, hepatocyte necrosis and exhibits anti-fibrotic effects. j-1063 has poten... |
|
T79603 |
3,7-DMF
|
|
TGF-beta/Smad
|
|
3,7-Dimethylfumarate (3,7-DMF) serves as an oral inhibitor of transforming growth factor-beta 1 (TGF-β1)-mediated hepatic stellate cell (HSC) activation. By inducing antioxidant gene expression and scavenging reactive ox... |
|
T79695 |
NLRP3-IN-19
|
NLRP3-IN-19 |
NOD-like Receptor (NLR)
|
|
JT001 (NLRP3-IN-19) is a potent, specific, and orally active NLRP3 inhibitor that impedes the assembly of the NLRP3 inflammasome. This action results in the suppression of cytokine release and prevention of pyroptosis. J... |
|
T69035 |
Camostat free base
|
|
|
|
Camostat, also known as FOY 305, is a serine protease inhibitor. Camostat is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or... |
|
T79696 |
JT001 sodium
|
NLRP3-IN-19 sodium |
NOD-like Receptor (NLR)
|
|
JT001 (NLRP3-IN-19) sodium is a potent, specific, and orally active NLRP3 inhibitor that impedes the assembly of the NLRP3 inflammasome, thus curbing cytokine release and averting pyroptosis. It is utilized in research f... |
|
T61949 |
Evogliptin
|
|
|
|
Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes s... |
|
T35807 |
C18 dihydro Ceramide (d18:0/18:0)
|
C18 dihydro Ceramide (d18:0/18:0),Cer(d18:0/18:0) |
|
|
C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. [1] Increased C18 dihydroceramide lipid levels lead to increased triacylglycer... |
|
T64144 |
FXR antagonist 1
|
|
|
|
FXR antagonist 1 is a selective, orally active intestinal FXR antagonist with an IC50 value of 2.1 μM. FXR antagonist 1 antagonises intestinal FXR and selectively inhibits intestinal FXR signalling by feedback activation... |
|
T69686 |
BMS-986318
|
|
|
|
BMS-986318 is a potent nonbile acid FXR agonist, displaying EC50 values of 53 nM and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. It exhibits a favorable ADME profile and shows effectiveness in mouse mo... |
|
T60854 |
ENMD-1068 hydrochloride
|
|
|
|
ENMD-1068 hydrochloride, a selective protease-activated receptor 2 (PAR2) antagonist, inhibits TGF-β1/Smad signaling, thereby reducing hepatic stellate cell activation and collagen expression. It also suppresses the prol... |
|
T79731 |
MLKL-IN-6
|
|
Necroptosis
|
|
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein. It effectively prevents MLKL phosphorylation and oligomerization, which are crit... |
|
T83682 |
Tat-Gap 19 TFA
|
|
|
|
Tat-Gap 19, a peptide inhibitor of connexin43 (Cx43) hemichannels, is derived from the HIV-1 Tat protein transduction domain fused with a nine-amino acid sequence from Cx43 residues 128-136. This compound, at a concentra... |
|
T36673 |
CC 401 dihydrochloride
|
|
|
|
High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase... |
